Malaria Clinical Trial
— START-IPTOfficial title:
'SCHOOL-BASED TREATMENT WITH ACT TO REDUCE TRANSMISSION' (START-IPT): Evaluation of the Community Impact of Intermittent Preventive Treatment for Malaria in Ugandan Children: a Cluster Randomised Trial
We propose to evaluate the community-level impact of intermittent preventive treatment (IPT) for malaria in schoolchildren on clinical outcomes and malaria transmission, using a cluster-randomised design in Jinja, Uganda. Dihydroartemisinin-piperaquine (DP) will be administered to schoolchildren monthly for up to six rounds of treatment during one school year. Outcomes will be measured using surveys of communities, schoolchildren, and mosquito vectors. Our proposal also includes health service research to evaluate the potential feasibility of taking the programme to scale, which will guide future research and implementation of the intervention, and help shape policies in Uganda and elsewhere in Africa.
| Status | Completed |
| Enrollment | 10746 |
| Est. completion date | April 2015 |
| Est. primary completion date | April 2015 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 5 Years and older |
| Eligibility |
For IPT intervention Inclusion Criteria: 1. Student enrolled in a participating intervention school. 2. Willingness of parent/guardian to provide written informed consent. 3. Provision of written assent by the student (aged 8 years or above). Exclusion Criteria: 1. Age < 5 years 2. Known allergy or history of adverse reaction to DP 3. Menarche in female students 4. Weight < 11 kg 5. History of cardiac problems or fainting 6. Family history of long QT syndrome 7. Current use of medications known to prolong the QT interval 8. Not able to locate parent or guardian, after at least three attempts including parent/teacher association (PTA) meetings and home visits 9. Not able to locate the student at school, after at least three attempts |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
| Country | Name | City | State |
|---|---|---|---|
| Uganda | Infectious Diseases Research Collaboration | Kampala |
| Lead Sponsor | Collaborator |
|---|---|
| London School of Hygiene and Tropical Medicine | Infectious Diseases Research Collaboration, Uganda, University of California, San Francisco, University of Durham |
Uganda,
Nankabirwa J, Cundill B, Clarke S, Kabatereine N, Rosenthal PJ, Dorsey G, Brooker S, Staedke SG. Efficacy, safety, and tolerability of three regimens for prevention of malaria: a randomized, placebo-controlled trial in Ugandan schoolchildren. PLoS One. 2010 Oct 19;5(10):e13438. doi: 10.1371/journal.pone.0013438. — View Citation
Nankabirwa JI, Wandera B, Amuge P, Kiwanuka N, Dorsey G, Rosenthal PJ, Brooker SJ, Staedke SG, Kamya MR. Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial. Clin Infect Dis. 2014 May;58(10):1404-12. doi: 10.1093/cid/ciu150. Epub 2014 Mar 12. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Parasite prevalence measured by microscopy + LAMP in the final community survey | Proportion of samples that are positive for asexual parasites by microscopy and LAMP | Approximately 1-4 months after completion of the intervention | No |
| Other | Prevalence of anaemia in children under-five in the final community survey | Proportion of haemoglobin measurements categorised as mild, moderate, and severe anaemia according to WHO age-stratified guidelines, in children under five | Approximately 1-4 months after completion of the intervention | No |
| Other | Prevalence of gametocytaemia in the final community survey | Proportion of thick blood smears that are positive for sexual parasites | Approximately 1-4 months after completion of the intervention | No |
| Other | Sporozoite rate in the entomology survey | Proportion of An gambiae infected with sporozoites | Over approximately 1 year | No |
| Other | Prevalence of serious adverse events (SAEs) | Proportion of children enrolled in the intervention experiencing any SAEs out of the total number of children enrolled; collected during prospective monitoring | Over approximately 6 months, during the delivery of the intervention | Yes |
| Primary | Parasite prevalence measured by microscopy in final community survey | Proportion of thick blood smears that are positive for asexual parasites, as measured by microscopy. | Approximately 1-4 months after completion of the intervention | No |
| Secondary | Entomologic inoculation rate (EIR) in the entomology survey | EIR will be defined as the number of infectious bites per person per year (the human biting rate multiplied by the sporozoite rate). | Over approximately 1 year | No |
| Secondary | Parasite prevalence measured by microscopy in the final school survey | Proportion of thick blood smears that are positive for asexual parasites, as measured by microscopy. | During the final 1 month of the intervention | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
| Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
| Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
| Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
| Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
| Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
| Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
| Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
| Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
| Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
| Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
| Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
| Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
| Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
| Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
| Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
| Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
| Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
| Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
| Completed |
NCT02315690 -
Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in Swaziland
|
Phase 3 |